Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

Glioblastoma (GB) remains the most fatal brain tumor characterized by a high infiltration rate and treatment resistance. Overexpression and/or mutation of receptor tyrosine kinases is common in GB, which subsequently leads to the activation of many downstream pathways that have a critical impact on...

Full description

Bibliographic Details
Main Authors: Julie Bolcaen, Shankari Nair, Cathryn H. S. Driver, Tebatso M. G. Boshomane, Thomas Ebenhan, Charlot Vandevoorde
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Pharmaceuticals
Subjects:
targeted radionuclide therapy
glioblastoma
radiochemistry
theranostics
molecular imaging
tyrosine kinases
Online Access:https://www.mdpi.com/1424-8247/14/7/626

Internet

https://www.mdpi.com/1424-8247/14/7/626

Similar Items